Genentech says its best-selling cancer drug continues to push the company's growth and shows future promise. It has begun Phase III testing on Avastin as a treatment for a specific form of lung cancer and as a second-line treatment for colon cancer. The biotech also is talking to the FDA about Avastin as a possible combined therapy for advanced kidney cancer.

Full Story:

Related Summaries